Effects of Add-On Ultramicronized N-Palmitol Ethanol Amide in Patients Suffering of Migraine With Aura: A Pilot Study

• Published in: Frontiers in neurology 2018-08, Vol.9, p.674-674
• Main Authors: Chirchiglia, Domenico, Cione, Erika, Caroleo, Maria C, Wang, Minyan, Di Mizio, Giulio, Faedda, Noemi, Giacolini, Teodosio, Siviglia, Serena, Guidetti, Vincenzo, Gallelli, Luca
• Format: Article
• Language: English
• Subjects: clinical trial; efficacy; Migraine with aura; Neurology; pain; safety; ultramicronized palmitoyl ethanol amide
• ISSN: 1664-2295; 1664-2295
• DOI: 10.3389/fneur.2018.00674

Palmitoyl ethanol amide (PEA) is an endogenously produced substance showing anti-nociceptive effect through both receptor and non-receptor mediated effects at the level of different cellular and tissue sites. This study showed the results of a single blind study that was conducted to evaluate both the safety and the efficacy of ultramicronized PEA (umPEA; 1,200 mg/day) for up 90 days in patients suffering of Migraine with Aura (MA) treated with NSAIDs. A total of 20 patients, 8 male (33-56-years, average 41.4 ± 7.8) and 12 female (19-61-years, average 38.5 ± 11.9) with MA were admitted to our observation and diagnosed according to ICHD-3 criteria, they received umPEA (1,200 mg/day) in combination with NSAIDs for up to 90 days. They were revaluated at 30, 60, and 90 days after treatment. umPEA administration induced a statistically significant and time dependent pain relief. In particular, these effects were evident at 60 days (male = 0.01189; female =